ALAMEDA, Calif.-- (BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that ...
* Biotime receives DSMB approval to start third patient cohort in clinical trial for dry-AMD; commences patient enrollment in the U.S. * Biotime Inc - Will start enrolling patients in cohort 3 in ...
BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results